Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Aliment Pharmacol Ther

Retrieve available abstracts of 361 articles:
HTML format
Text format



Single Articles


    August 2018
  1. DE FRANCISCO R, Castano-Garcia A, Martinez-Gonzalez S, Perez-Martinez I, et al
    Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Aug 10. doi: 10.1111/apt.14933.
    PubMed     Text format     Abstract available


  2. GAGNIERE C, Bourrier A, Seksik P, Gornet JM, et al
    Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the GETAID.
    Aliment Pharmacol Ther. 2018 Aug 2. doi: 10.1111/apt.14926.
    PubMed     Text format     Abstract available


  3. SAVOYE G, Fumery M, Gower-Rousseau C
    Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery? Authors' reply.
    Aliment Pharmacol Ther. 2018;48:384-385.
    PubMed     Text format    


  4. JULSGAARD M, Kjeldsen J, Brock B, Baumgart DC, et al
    Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:386-388.
    PubMed     Text format    


  5. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48:388-389.
    PubMed     Text format    


  6. MYRELID P
    Editorial: post-operative complications in elderly onset inflammatory bowel disease-what is surgery, what is disease, and what is delay of surgery?
    Aliment Pharmacol Ther. 2018;48:383-384.
    PubMed     Text format    


  7. PEYRIN-BIROULET L, Lopez A, Cummings JRF, Dignass A, et al
    Review article: treating-to-target for inflammatory bowel disease-associated anaemia.
    Aliment Pharmacol Ther. 2018 Aug 1. doi: 10.1111/apt.14922.
    PubMed     Text format     Abstract available


  8. ERIKSSON C, Henriksson I, Brus O, Zhulina Y, et al
    Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population-based cohort study.
    Aliment Pharmacol Ther. 2018 Aug 1. doi: 10.1111/apt.14920.
    PubMed     Text format     Abstract available


    July 2018
  9. KOTZE PG, Ma C, Almutairdi A, Al-Darmaki A, et al
    Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jul 31. doi: 10.1111/apt.14919.
    PubMed     Text format     Abstract available


  10. JOOSSE ME, Aardoom MA, Kemos P, Turner D, et al
    Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN.
    Aliment Pharmacol Ther. 2018 Jul 8. doi: 10.1111/apt.14893.
    PubMed     Text format     Abstract available


  11. STAPERSMA L, van den Brink G, Szigethy EM, Escher JC, et al
    Systematic review with meta-analysis: anxiety and depression in children and adolescents with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jul 8. doi: 10.1111/apt.14865.
    PubMed     Text format     Abstract available


  12. ANSARI AR, Aziz A
    Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;48:97-98.
    PubMed     Text format    


  13. FRIEDMAN AB, Sparrow MP
    Editorial: an argument for low-dose thiopurine allopurinol combination use as first-line therapy in inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2018;48:98-99.
    PubMed     Text format    


    June 2018
  14. HANLON I, Hewitt C, Bell K, Phillips A, et al
    Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 14. doi: 10.1111/apt.14840.
    PubMed     Text format     Abstract available


  15. VAN DEN BRINK G, Stapersma L, Vlug LE, Rizopolous D, et al
    Clinical disease activity is associated with anxiety and depressive symptoms in adolescents and young adults with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 13. doi: 10.1111/apt.14832.
    PubMed     Text format     Abstract available


  16. PARK KT, Sceats L, Dehghan M, Trickey AW, et al
    Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jun 7. doi: 10.1111/apt.14842.
    PubMed     Text format     Abstract available


  17. GONCALVES J, Santos M, Acurcio R, Iria I, et al
    Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
    Aliment Pharmacol Ther. 2018 Jun 5. doi: 10.1111/apt.14808.
    PubMed     Text format     Abstract available


  18. BAE JM, Lee HH, Lee BI, Lee KM, et al
    Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Aliment Pharmacol Ther. 2018 Jun 5. doi: 10.1111/apt.14822.
    PubMed     Text format     Abstract available


  19. ALUKAIDEY S, Heerasing N
    Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice.
    Aliment Pharmacol Ther. 2018;47:1539-1540.
    PubMed     Text format    


  20. UNGARO R, Colombel JF
    Editorial: de novo inflammatory bowel disease following bariatric surgery-potential implications for research and clinical practice. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1540.
    PubMed     Text format    


    May 2018
  21. TSE CS, Loftus EV Jr, Raffals LE, Gossard AA, et al
    Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 May 28. doi: 10.1111/apt.14829.
    PubMed     Text format     Abstract available


  22. SACLEUX SC, Sarter H, Fumery M, Charpentier C, et al
    Post-operative complications in elderly onset inflammatory bowel disease: a population-based study.
    Aliment Pharmacol Ther. 2018 May 8. doi: 10.1111/apt.14790.
    PubMed     Text format     Abstract available


  23. SEHGAL P, Colombel JF, Aboubakr A, Narula N, et al
    Systematic review: safety of mesalazine in ulcerative colitis.
    Aliment Pharmacol Ther. 2018 May 3. doi: 10.1111/apt.14688.
    PubMed     Text format     Abstract available


  24. FRAGAKI M, Karmiris K
    Editorial: monitoring vedolizumab trough serum concentration in inflammatory bowel disease-following the fate of anti-TNF-alpha agents?
    Aliment Pharmacol Ther. 2018;47:1323-1324.
    PubMed     Text format    


  25. PAVLIDIS P, Graham J, Gulati S, Dubois P, et al
    Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:1422-1423.
    PubMed     Text format    


  26. MANOSA M, Domenech E
    Letter: phenotype and natural history of elderly onset inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1421-1422.
    PubMed     Text format    


  27. CHRISTENSEN B, Gibson PR, Rubin DT
    Letter: vedolizumab for autoimmune liver disease associated inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:1423-1424.
    PubMed     Text format    


  28. EVERHOV AH, Ludvigsson JF, Olen O
    Letter: phenotype and natural history of elderly onset inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:1420-1421.
    PubMed     Text format    


    April 2018
  29. MA C, Guizzetti L, Panaccione R, Fedorak RN, et al
    Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Apr 25. doi: 10.1111/apt.14672.
    PubMed     Text format     Abstract available


  30. WHITE JR, Phillips F, Monaghan T, Fateen W, et al
    Review article: novel oral-targeted therapies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Apr 19. doi: 10.1111/apt.14669.
    PubMed     Text format     Abstract available


  31. KURNOOL S, Nguyen NH, Proudfoot J, Dulai PS, et al
    High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Apr 17. doi: 10.1111/apt.14665.
    PubMed     Text format     Abstract available


  32. MONINUOLA OO, Milligan W, Lochhead P, Khalili H, et al
    Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation.
    Aliment Pharmacol Ther. 2018 Apr 5. doi: 10.1111/apt.14606.
    PubMed     Text format     Abstract available


  33. TALEBAN S
    Editorial: older-onset inflammatory bowel disease-is it time to start looking beyond a number?
    Aliment Pharmacol Ther. 2018;47:1034-1035.
    PubMed     Text format    


  34. MAGRO F, Sousa HT
    Editorial: ulcerative colitis submucosal fibrosis and inflammation: more than just strictures.
    Aliment Pharmacol Ther. 2018;47:1033-1034.
    PubMed     Text format    


    March 2018
  35. TANG MT, Keir ME, Erickson R, Stefanich EG, et al
    Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-beta7 integrin therapy for inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Mar 30. doi: 10.1111/apt.14631.
    PubMed     Text format     Abstract available


  36. VOLLEBREGT PF, van Bodegraven AA, Markus-de Kwaadsteniet TML, van der Horst D, et al
    Impacts of perianal disease and faecal incontinence on quality of life and employment in 1092 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Mar 9. doi: 10.1111/apt.14599.
    PubMed     Text format     Abstract available


  37. UNGARO R, Fausel R, Chang HL, Chang S, et al
    Bariatric surgery is associated with increased risk of new-onset inflammatory bowel disease: case series and national database study.
    Aliment Pharmacol Ther. 2018 Mar 7. doi: 10.1111/apt.14569.
    PubMed     Text format     Abstract available


  38. WALKER GJ, Moore L, Heerasing N, Hendy P, et al
    Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study.
    Aliment Pharmacol Ther. 2018 Mar 5. doi: 10.1111/apt.14563.
    PubMed     Text format     Abstract available


  39. LAHARIE D, Riviere P
    Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:689-690.
    PubMed     Text format    


  40. QIU XY, Lu MJ, Zhang HJ
    Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease-Authors' reply.
    Aliment Pharmacol Ther. 2018;47:690-691.
    PubMed     Text format    


  41. LOBATON T, De Vos M
    Editorial: infliximab trough levels and histological healing in ulcerative colitis-a step towards personalised biologic therapy.
    Aliment Pharmacol Ther. 2018;47:855-856.
    PubMed     Text format    


    February 2018
  42. BARRE A, Colombel JF, Ungaro R
    Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Feb 12. doi: 10.1111/apt.14550.
    PubMed     Text format     Abstract available


  43. BALLOU S, Hirsch W, Singh P, Rangan V, et al
    Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014.
    Aliment Pharmacol Ther. 2018 Feb 7. doi: 10.1111/apt.14551.
    PubMed     Text format     Abstract available


  44. GORDON IO, Agrawal N, Willis E, Goldblum JR, et al
    Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation.
    Aliment Pharmacol Ther. 2018 Feb 6. doi: 10.1111/apt.14526.
    PubMed     Text format     Abstract available


  45. RIBALDONE DG, Saracco GM, Astegiano M, Pellicano R, et al
    Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.
    Aliment Pharmacol Ther. 2018;47:448-449.
    PubMed     Text format    


  46. COTE-DAIGNEAULT J, Luong ML, Colombel JF, Peerani F, et al
    Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications.
    Aliment Pharmacol Ther. 2018;47:446-447.
    PubMed     Text format    


  47. KHAN N, Lewis JD
    Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications-authors' reply.
    Aliment Pharmacol Ther. 2018;47:448.
    PubMed     Text format    


  48. PAPAMICHAEL K, Cheifetz AS
    Editorial: early post-induction anti-TNF drug monitoring can predict long-term therapeutic outcomes in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:436-437.
    PubMed     Text format    


  49. TSAI HH
    Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class?
    Aliment Pharmacol Ther. 2018;47:539-540.
    PubMed     Text format    


  50. BONOVAS S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, et al
    Editorial: tofacitinib and biologics for moderate-to-severe ulcerative colitis-what is best in class? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:540-541.
    PubMed     Text format    


  51. BARCLAY ML, Stamp LK
    Editorial: vedolizumab as a treatment and cause of extra-intestinal manifestations of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:535-536.
    PubMed     Text format    


    January 2018
  52. YACOUB W, Williet N, Pouillon L, Di-Bernado T, et al
    Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study.
    Aliment Pharmacol Ther. 2018 Jan 31. doi: 10.1111/apt.14548.
    PubMed     Text format     Abstract available


  53. CHRISTENSEN B, Micic D, Gibson PR, Yarur A, et al
    Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.
    Aliment Pharmacol Ther. 2018 Jan 29. doi: 10.1111/apt.14525.
    PubMed     Text format     Abstract available


  54. MANOSA M, Calafat M, de Francisco R, Garcia C, et al
    Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study.
    Aliment Pharmacol Ther. 2018 Jan 25. doi: 10.1111/apt.14494.
    PubMed     Text format     Abstract available


  55. WALJEE AK, Liu B, Sauder K, Zhu J, et al
    Predicting corticosteroid-free endoscopic remission with vedolizumab in ulcerative colitis.
    Aliment Pharmacol Ther. 2018 Jan 22. doi: 10.1111/apt.14510.
    PubMed     Text format     Abstract available


  56. SWEENEY L, Moss-Morris R, Czuber-Dochan W, Meade L, et al
    Systematic review: psychosocial factors associated with pain in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018 Jan 22. doi: 10.1111/apt.14493.
    PubMed     Text format     Abstract available


  57. OLIVERA P, Sandborn WJ, Panes J, Baumann C, et al
    Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
    Aliment Pharmacol Ther. 2018 Jan 19. doi: 10.1111/apt.14514.
    PubMed     Text format     Abstract available


  58. COLIZZO FP, Friedman LS
    Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2018;47:143-144.
    PubMed     Text format    


  59. BROEKMAN MMTJ, Wanten GJ, de Jong DJ
    Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:130-131.
    PubMed     Text format    


  60. SELINGER CP, Parkes GC, Raine T
    Editorial: avoiding corticosteroids in the treatment of inflammatory bowel disease-Author's reply.
    Aliment Pharmacol Ther. 2018;47:145.
    PubMed     Text format    


  61. WILLINGTON AJ, Gearry RB
    Editorial: thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype-the perils of ageing.
    Aliment Pharmacol Ther. 2018;47:129-130.
    PubMed     Text format    


  62. MURRAY CD
    Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine.
    Aliment Pharmacol Ther. 2018;47:141-142.
    PubMed     Text format    


  63. MEIJER B, de Boer NKH
    Letter: thiopurines - is less really more?
    Aliment Pharmacol Ther. 2018;47:149.
    PubMed     Text format    


  64. DING NS, Malietzis G, Hart AL
    Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine. Authors' reply.
    Aliment Pharmacol Ther. 2018;47:142-143.
    PubMed     Text format    


  65. EBERHARDSON M, Soderling JK, Olen O
    Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy? Authors' reply.
    Aliment Pharmacol Ther. 2018;47:147-148.
    PubMed     Text format    


  66. RIBALDONE DG, Saracco G, Astegiano M, Pellicano R, et al
    Letter: biologics treatment in Crohn's disease and risk of bowel resection-what about the patients who stop anti-TNF therapy?
    Aliment Pharmacol Ther. 2018;47:146-147.
    PubMed     Text format    


  67. LANG BM, Biedermann L, van Haaften WT, de Valliere C, et al
    Genetic polymorphisms associated with smoking behaviour predict the risk of surgery in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2018;47:55-66.
    PubMed     Text format     Abstract available


  68. VANDE CASTEELE N, Feagan BG, Vermeire S, Yassine M, et al
    Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2018;47:229-237.
    PubMed     Text format     Abstract available


  69. BAR-YOSEPH H, Levhar N, Selinger L, Manor U, et al
    Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.
    Aliment Pharmacol Ther. 2018;47:212-218.
    PubMed     Text format     Abstract available


  70. NORDENVALL C, Olen O, Nilsson PJ, von Seth E, et al
    Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients.
    Aliment Pharmacol Ther. 2018;47:238-245.
    PubMed     Text format     Abstract available


    December 2017
  71. WILSON A, Jansen LE, Rose RV, Gregor JC, et al
    HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Dec 22. doi: 10.1111/apt.14483.
    PubMed     Text format     Abstract available


  72. TADBIRI S, Peyrin-Biroulet L, Serrero M, Filippi J, et al
    Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
    Aliment Pharmacol Ther. 2017 Dec 18. doi: 10.1111/apt.14419.
    PubMed     Text format     Abstract available


  73. PAPAMICHAEL K, Rakowsky S, Rivera C, Cheifetz AS, et al
    Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 6. doi: 10.1111/apt.14458.
    PubMed     Text format     Abstract available


  74. SCHMITZ EMH, Boekema PJ, Straathof JWA, van Renswouw DC, et al
    Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
    Aliment Pharmacol Ther. 2017 Dec 5. doi: 10.1111/apt.14453.
    PubMed     Text format     Abstract available


  75. LU MJ, Qiu XY, Mao XQ, Li XT, et al
    Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14436.
    PubMed     Text format     Abstract available


  76. BONOVAS S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, et al
    Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14449.
    PubMed     Text format     Abstract available


  77. SINGH S, Fumery M, Sandborn WJ, Murad MH, et al
    Systematic review and network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Dec 4. doi: 10.1111/apt.14422.
    PubMed     Text format     Abstract available


  78. LOGAN M, Ijaz UZ, Hansen R, Gerasimidis K, et al
    Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format    


  79. FEATHERS A, Swaminath A, Ananthakrishnan AN, Falzon L, et al
    Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format    


  80. DOMENECH E, Canete F, Manosa M
    Editorial: therapeutic drug monitoring for anti-TNF agents-has it all been said?
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format    


  81. MARTINEAU C, Flourie B, Wils P, Vaysse T, et al
    Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format     Abstract available


  82. MITREV N, Vande Casteele N, Seow CH, Andrews JM, et al
    Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;46.
    PubMed     Text format     Abstract available


    November 2017
  83. YU H, MacIsaac D, Wong JJ, Sellers ZM, et al
    Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
    Aliment Pharmacol Ther. 2017 Nov 22. doi: 10.1111/apt.14430.
    PubMed     Text format     Abstract available


  84. COLOMBEL JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, et al
    Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Nov 21. doi: 10.1111/apt.14420.
    PubMed     Text format     Abstract available


  85. AYUBI E, Safiri S
    Letter: the outcome of ulcerative colitis patients undergoing pouch surgery may be determined by pre-surgical factors.
    Aliment Pharmacol Ther. 2017;46:901-902.
    PubMed     Text format    


  86. YANAI H, Ben-Shachar S, Mlynarsky L, Godny L, et al
    Letter: the outcome of ulcerative colitis patients undergoing pouch surgery may be determined by pre-surgical factors. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:902-903.
    PubMed     Text format    


  87. GOUYNOU C, Peyrin-Biroulet L
    Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients.
    Aliment Pharmacol Ther. 2017;46:1019-1020.
    PubMed     Text format    


  88. FEATHERS A, Swaminath A, Ananthakrishnan AN, Falzon L, et al
    Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;46:1026-1027.
    PubMed     Text format    


  89. DAI C, Cao Q, Jiang M
    Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:1025-1026.
    PubMed     Text format    


  90. FIORINO G, Correale C, Radice S, Allocca M, et al
    Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.
    Aliment Pharmacol Ther. 2017;46:903-905.
    PubMed     Text format    


  91. ERIKSSON C, Cao Y, Rundquist S, Zhulina Y, et al
    Editorial: do thiopurines and biologics decrease the risk of colectomy? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:897-898.
    PubMed     Text format    


  92. KOMAKI Y, Yamada A, Komaki F, Sakuraba A, et al
    Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.
    Aliment Pharmacol Ther. 2017;46:905-906.
    PubMed     Text format    


  93. H ALLIN K, Jess T
    Editorial: do thiopurines and biologics decrease the risk of colectomy?
    Aliment Pharmacol Ther. 2017;46:896-897.
    PubMed     Text format    


  94. NAKASE H, Motoya S, Matsumoto T, Watanabe K, et al
    Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
    Aliment Pharmacol Ther. 2017;46:873-882.
    PubMed     Text format     Abstract available


  95. DING NS, Malietzis G, Lung PFC, Penez L, et al
    The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm.
    Aliment Pharmacol Ther. 2017;46:883-891.
    PubMed     Text format     Abstract available


  96. CARDING SR, Davis N, Hoyles L
    Review article: the human intestinal virome in health and disease.
    Aliment Pharmacol Ther. 2017;46:800-815.
    PubMed     Text format     Abstract available


    October 2017
  97. KUMP P, Wurm P, Grochenig HP, Wenzl H, et al
    The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Oct 20. doi: 10.1111/apt.14387.
    PubMed     Text format     Abstract available


  98. MCILROY J, Ianiro G, Mukhopadhya I, Hansen R, et al
    Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management.
    Aliment Pharmacol Ther. 2017 Oct 16. doi: 10.1111/apt.14384.
    PubMed     Text format     Abstract available


  99. LO B, Prosberg MV, Gluud LL, Chan W, et al
    Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index.
    Aliment Pharmacol Ther. 2017 Oct 9. doi: 10.1111/apt.14373.
    PubMed     Text format     Abstract available


  100. SWAMINATH A, Feathers A, Ananthakrishnan AN, Falzon L, et al
    Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:645-656.
    PubMed     Text format     Abstract available


  101. ACTIS GC, Pellicano R
    Letter: Cuban immigrants to the US developing IBD have a progressive shortening of the lag between time of arrival and disease onset.
    Aliment Pharmacol Ther. 2017;46:768.
    PubMed     Text format    


  102. DAMAS O, Abreu MT
    Letter: Cuban immigrants to the US developing IBD have a progressive shortening of the lag between time of arrival and disease onset. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:768-769.
    PubMed     Text format    


  103. LUNG PFC, Ng SC
    Editorial: challenges in the development of a magnetic resonance imaging index for fistulising Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:696.
    PubMed     Text format    


    September 2017
  104. BERNSTEIN CN
    Review article: changes in the epidemiology of inflammatory bowel disease-clues for aetiology.
    Aliment Pharmacol Ther. 2017 Sep 26. doi: 10.1111/apt.14338.
    PubMed     Text format     Abstract available


  105. SELINGER CP, Parkes GC, Bassi A, Fogden E, et al
    A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Sep 26. doi: 10.1111/apt.14334.
    PubMed     Text format     Abstract available


  106. BROEKMAN MMTJ, Coenen MJH, Wanten GJ, van Marrewijk CJ, et al
    Risk factors for thiopurine-induced myelosuppression and infections in inflammatory bowel disease patients with a normal TPMT genotype.
    Aliment Pharmacol Ther. 2017 Sep 15. doi: 10.1111/apt.14323.
    PubMed     Text format     Abstract available


  107. XU L, Lochhead P, Ko Y, Claggett B, et al
    Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Sep 11. doi: 10.1111/apt.14291.
    PubMed     Text format     Abstract available


  108. ALEXAKIS C, Kumar S, Saxena S, Hotopf M, et al
    Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care-authors' reply.
    Aliment Pharmacol Ther. 2017;46:554-555.
    PubMed     Text format    


  109. KEEFER L
    Editorial: depression in the setting of inflammatory bowel disease means we have failed to provide early, effective, psychosocial care.
    Aliment Pharmacol Ther. 2017;46:553-554.
    PubMed     Text format    


  110. GRACIE DJ, Derwa Y, Hamlin PJ, Ford AC, et al
    Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:633-634.
    PubMed     Text format    


  111. SHANAHAN F
    Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts?
    Aliment Pharmacol Ther. 2017;46:632-633.
    PubMed     Text format    


  112. LIM MH, Radford-Smith GL
    Editorial: faecal microbiota transplantation for ulcerative colitis-not quite there yet?
    Aliment Pharmacol Ther. 2017;46:630-631.
    PubMed     Text format    


  113. COSTELLO SP, Soo W, Bryant RV, Jairath V, et al
    Editorial: faecal microbiota transplantation for ulcerative colitis-not quite there yet? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:631-632.
    PubMed     Text format    


  114. EBERHARDSON M, Soderling JK, Neovius M, Cars T, et al
    Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study.
    Aliment Pharmacol Ther. 2017;46:589-598.
    PubMed     Text format     Abstract available


  115. SAMAAN MA, Puylaert CAJ, Levesque BG, Zou GY, et al
    The development of a magnetic resonance imaging index for fistulising Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:516-528.
    PubMed     Text format     Abstract available


  116. SPEIGHT RA, Mansfield JC
    Editorial: how effective is vedolizumab in the 'real world'?
    Aliment Pharmacol Ther. 2017;46:555-556.
    PubMed     Text format    


    August 2017
  117. ERIKSSON C, Cao Y, Rundquist S, Zhulina Y, et al
    Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Orebro, Sweden, 1963-2010.
    Aliment Pharmacol Ther. 2017 Aug 17. doi: 10.1111/apt.14268.
    PubMed     Text format     Abstract available


  118. KHAN N, Shah Y, Trivedi C, Lewis JD, et al
    Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications.
    Aliment Pharmacol Ther. 2017 Aug 14. doi: 10.1111/apt.14257.
    PubMed     Text format     Abstract available


  119. DAMAS OM, Schwartz SJ, Abreu MT
    Editorial: migration studies to determine risk and cause of inflammatory bowel disease-authors' reply.
    Aliment Pharmacol Ther. 2017;46:467.
    PubMed     Text format    


  120. KUENZIG ME, Benchimol EI
    Editorial: migration studies to determine risk and cause of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017;46:465-466.
    PubMed     Text format    


  121. WISKIN AE, Sandhu BK
    Editorial: changing nature of paediatric IBD-new insights from Irish data.
    Aliment Pharmacol Ther. 2017;46:457-458.
    PubMed     Text format    


  122. SEOW CH, Panaccione R
    Editorial: different tests for different drugs in Crohn's disease, or different tests for different people?
    Aliment Pharmacol Ther. 2017;46:463-464.
    PubMed     Text format    


  123. HUSSEY S
    Editorial: changing nature of paediatric IBD-new insights from Irish data. Author's reply.
    Aliment Pharmacol Ther. 2017;46:458-459.
    PubMed     Text format    


  124. WARD MG, Irving PM
    Editorial: different tests for different drugs in Crohn's disease, or different tests for different people? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:465.
    PubMed     Text format    


  125. WILLIAMS HRT, Orchard TR
    Editorial: volatile organic compounds in breath for monitoring IBD-longitudinal studies are essential.
    Aliment Pharmacol Ther. 2017;46:371-372.
    PubMed     Text format    


  126. SMOLINSKA A, van Schooten FJ
    Editorial: volatile organic compounds in breath for monitoring IBD-longitudinal studies are essential. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:372.
    PubMed     Text format    


    July 2017
  127. COATES MD, Tekin I, Vrana KE, Mawe GM, et al
    Review article: the many potential roles of intestinal serotonin (5-hydroxytryptamine, 5-HT) signalling in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jul 24. doi: 10.1111/apt.14226.
    PubMed     Text format     Abstract available


  128. UNGARO RC, Colombel JF
    Editorial: biologics in inflammatory bowel disease-time for direct comparisons.
    Aliment Pharmacol Ther. 2017;46:68-69.
    PubMed     Text format    


  129. ANDREWS JM
    Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities?
    Aliment Pharmacol Ther. 2017;46:201-202.
    PubMed     Text format    


  130. CRAMER H, Dobos G, Langhorst J
    Editorial: yoga for QoL in ulcerative colitis-any better than other supportive activities? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:202-203.
    PubMed     Text format    


  131. VAN HAAFTEN WT, Mortensen JH, Karsdal MA, Bay-Jensen AC, et al
    Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:26-39.
    PubMed     Text format     Abstract available


  132. WARD MG, Warner B, Unsworth N, Chuah SW, et al
    Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
    Aliment Pharmacol Ther. 2017;46:150-161.
    PubMed     Text format     Abstract available


  133. ANANTHAKRISHNAN AN, Sakuraba A, Barnes EL, Pekow J, et al
    The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
    Aliment Pharmacol Ther. 2017;46:162-168.
    PubMed     Text format     Abstract available


  134. IMPERATORE N, Testa A, Caporaso N, Rispo A, et al
    Letter: anti-TNF dose de-escalation in Crohn's disease-a case-by-case decision.
    Aliment Pharmacol Ther. 2017;46:212.
    PubMed     Text format    


  135. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Editorial: which iron preparation for patients with IBD? Authors' reply.
    Aliment Pharmacol Ther. 2017;46:195-196.
    PubMed     Text format    


  136. KENNEDY NA, Goodhand JR, Rampton DS
    Editorial: which iron preparation for patients with IBD?
    Aliment Pharmacol Ther. 2017;46:194-195.
    PubMed     Text format    


  137. PORTER CK, Riddle MS, Hooper TI
    Editorial: the Millennium study cohort-evaluating environmental determinates of IBD in the 21st Century. Authors' reply.
    Aliment Pharmacol Ther. 2017;46:64-65.
    PubMed     Text format    


  138. KAPLAN GG
    Editorial: the Millennium study cohort-evaluating environmental determinates of IBD in the 21st century.
    Aliment Pharmacol Ther. 2017;46:63-64.
    PubMed     Text format    


  139. WANG S, Lin J
    Letter: determining the dominant role of environmental factors in UC development.
    Aliment Pharmacol Ther. 2017;46:77-78.
    PubMed     Text format    


    June 2017
  140. YANAI H, Ben-Shachar S, Mlynarsky L, Godny L, et al
    The outcome of ulcerative colitis patients undergoing pouch surgery is determined by pre-surgical factors.
    Aliment Pharmacol Ther. 2017 Jun 30. doi: 10.1111/apt.14205.
    PubMed     Text format     Abstract available


  141. DERWA Y, Gracie DJ, Hamlin PJ, Ford AC, et al
    Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jun 27. doi: 10.1111/apt.14203.
    PubMed     Text format     Abstract available


  142. COSTELLO SP, Soo W, Bryant RV, Jairath V, et al
    Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jun 14. doi: 10.1111/apt.14173.
    PubMed     Text format     Abstract available


  143. AMIOT A, Serrero M, Peyrin-Biroulet L, Filippi J, et al
    One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
    Aliment Pharmacol Ther. 2017 Jun 8. doi: 10.1111/apt.14167.
    PubMed     Text format     Abstract available


  144. ALEXAKIS C, Kumar S, Saxena S, Pollok R, et al
    Systematic review and meta-analysis: the impact of a depressive state on disease course in adult inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Jun 2. doi: 10.1111/apt.14171.
    PubMed     Text format     Abstract available


  145. D'HAENS GR, Sandborn WJ, Zou G, Stitt LW, et al
    Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jun 1. doi: 10.1111/apt.14164.
    PubMed     Text format     Abstract available


  146. STIDHAM RW, Waljee AK
    Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1551-1552.
    PubMed     Text format    


  147. COLLINS PD
    Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer.
    Aliment Pharmacol Ther. 2017;45:1553-1554.
    PubMed     Text format    


  148. HOLT DQ, Moore GT, Strauss BJG, Hamilton AL, et al
    Editorial: visceral fat as a predictor of post-operative recurrence of Crohn's disease-Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1552-1553.
    PubMed     Text format    


  149. BONOVAS S, Fiorino G, Lytras T, Nikolopoulos G, et al
    Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply.
    Aliment Pharmacol Ther. 2017;45:1554-1555.
    PubMed     Text format    


  150. VANDE CASTEELE N, Gils A
    Editorial: variability in adalimumab trough and peak serum concentrations.
    Aliment Pharmacol Ther. 2017;45:1475-1476.
    PubMed     Text format    


  151. JAIRATH V, Feagan BG
    Editorial: the impact of the placebo effect in Crohn's disease - author's reply.
    Aliment Pharmacol Ther. 2017;45:1472.
    PubMed     Text format    


  152. BERNSTEIN CN
    Editorial: the impact of the placebo effect in Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1471-1472.
    PubMed     Text format    


  153. WARD MG, Gibson PR, Sparrow MP
    Editorial: variability in adalimumab trough and peak serum concentrations - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1476-1477.
    PubMed     Text format    


    May 2017
  154. DAMAS OM, Avalos DJ, Palacio AM, Gomez L, et al
    Inflammatory bowel disease is presenting sooner after immigration in more recent US immigrants from Cuba.
    Aliment Pharmacol Ther. 2017 May 19. doi: 10.1111/apt.14145.
    PubMed     Text format     Abstract available


  155. NORTON C, Czuber-Dochan W, Artom M, Sweeney L, et al
    Systematic review: interventions for abdominal pain management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 May 4. doi: 10.1111/apt.14108.
    PubMed     Text format     Abstract available


  156. CHRISTENSEN B, Sparrow MP
    Editorial: international consensus in clinical trial end-points in ulcerative colitis - clarity or just a step in clearing the fog?
    Aliment Pharmacol Ther. 2017;45:1274-1275.
    PubMed     Text format    


  157. LAMBA MJ, Tharayil VS, Gearry RB
    Editorial: inflammatory bowel disease risk reduction after migration - are early life events important?
    Aliment Pharmacol Ther. 2017;45:1367-1368.
    PubMed     Text format    


  158. NELSON A, Tsai HH
    Editorial: Clostridium difficile and inflammatory bowel disease - is it always a bad combination?
    Aliment Pharmacol Ther. 2017;45:1368-1369.
    PubMed     Text format    


  159. EVERHOV AH, Olen O, Ludvigsson JF
    Editorial: importance of definition of inflammatory bowel disease and an increased incidence in children.
    Aliment Pharmacol Ther. 2017;45:1369-1370.
    PubMed     Text format    


  160. HAWTHORNE AB
    Editorial: clinical benefits of vitamin D therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017;45:1365-1366.
    PubMed     Text format    


  161. MA C, Fedorak RN, Kaplan GG, Dieleman LA, et al
    Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
    Aliment Pharmacol Ther. 2017;45:1232-1243.
    PubMed     Text format     Abstract available


  162. HOLT DQ, Moore GT, Strauss BJ, Hamilton AL, et al
    Visceral adiposity predicts post-operative Crohn's disease recurrence.
    Aliment Pharmacol Ther. 2017;45:1255-1264.
    PubMed     Text format     Abstract available


  163. KHORRAMI S, Gisbert JP
    Editorial: accumulating data about ustekinumab in refractory Crohn's disease in real world experience.
    Aliment Pharmacol Ther. 2017;45:1374-1375.
    PubMed     Text format    


  164. KOMAKI Y, Yamada A, Komaki F, Micic D, et al
    Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1372.
    PubMed     Text format    


  165. FELWICK R, Cummings JRF
    Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:1370-1371.
    PubMed     Text format    


  166. SHIM HH, Seow CH
    Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum?
    Aliment Pharmacol Ther. 2017;45:1283-1284.
    PubMed     Text format    


  167. MITREV N, Kariyawasam V, Leong RW
    Editorial: infliximab trough cut-off for perianal Crohn's disease - another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle.
    Aliment Pharmacol Ther. 2017;45:1279-1280.
    PubMed     Text format    


  168. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Editorial: vedolizumab in pregnancy - is gut selectivity as good for baby as it is for mum? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1284.
    PubMed     Text format    


    April 2017
  169. RODA G, Narula N, Pinotti R, Skamnelos A, et al
    Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14063.
    PubMed     Text format     Abstract available


  170. BYE WA, Jairath V, Travis SPL
    Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14075.
    PubMed     Text format     Abstract available


  171. ROBLIN X, Boschetti G, Williet N, Nancey S, et al
    Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14106.
    PubMed     Text format     Abstract available


  172. COUGHLAN A, Wylde R, Lafferty L, Quinn S, et al
    A rising incidence and poorer male outcomes characterise early onset paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Apr 27. doi: 10.1111/apt.14070.
    PubMed     Text format     Abstract available


  173. CRAMER H, Schafer M, Schols M, Kocke J, et al
    Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Apr 5. doi: 10.1111/apt.14062.
    PubMed     Text format     Abstract available


  174. JAIRATH V, Casteele NV, Hindryckx P
    Letter: dose optimising infliximab in acute severe ulcerative colitis - authors' reply.
    Aliment Pharmacol Ther. 2017;45:1170-1171.
    PubMed     Text format    


  175. CHOY MC, De Cruz P
    Letter: dose optimising infliximab in acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017;45:1169-1170.
    PubMed     Text format    


  176. ANGELISON L, Marsal J, Hertervig E
    Letter: how to define remission in ulcerative colitis - histological remission should be considered. Authors' reply.
    Aliment Pharmacol Ther. 2017;45:1177-1178.
    PubMed     Text format    


  177. KILINCALP S, Ustun Y, Simsek Z
    Letter: how to define remission in ulcerative colitis - histological remission should be considered.
    Aliment Pharmacol Ther. 2017;45:1177.
    PubMed     Text format    


  178. YARUR AJ, Kanagala V, Stein DJ, Czul F, et al
    Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:933-940.
    PubMed     Text format     Abstract available


  179. VAN STEENBERGEN S, Bian S, Vermeire S, Van Assche G, et al
    Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study.
    Aliment Pharmacol Ther. 2017;45:923-932.
    PubMed     Text format     Abstract available


  180. ALLEN PB, Olivera P, Emery P, Moulin D, et al
    Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.
    Aliment Pharmacol Ther. 2017;45:1058-1072.
    PubMed     Text format     Abstract available


  181. KOMAKI Y, Yamada A, Komaki F, Micic D, et al
    Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:1043-1057.
    PubMed     Text format     Abstract available


  182. WARD MG, Thwaites PA, Beswick L, Hogg J, et al
    Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1135-1145.
    PubMed     Text format     Abstract available


  183. HAMMER T, Lophaven SN, Nielsen KR, von Euler-Chelpin M, et al
    Inflammatory bowel diseases in Faroese-born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development.
    Aliment Pharmacol Ther. 2017;45:1107-1114.
    PubMed     Text format     Abstract available


  184. JAIRATH V, Zou G, Parker CE, MacDonald JK, et al
    Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:1021-1042.
    PubMed     Text format     Abstract available


  185. ANANTHAKRISHNAN AN
    Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator? Author's reply.
    Aliment Pharmacol Ther. 2017;45:1168.
    PubMed     Text format    


  186. VEGH Z, Bessissow T, Afif W, Lakatos PL, et al
    Editorial: co-existing immune-mediated disease in inflammatory bowel diseases - a new disease severity indicator?
    Aliment Pharmacol Ther. 2017;45:1167.
    PubMed     Text format    


    March 2017
  187. CHOLAPRANEE A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
    Aliment Pharmacol Ther. 2017 Mar 22. doi: 10.1111/apt.14030.
    PubMed     Text format     Abstract available


  188. AKSAN A, Isik H, Radeke HH, Dignass A, et al
    Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 21. doi: 10.1111/apt.14043.
    PubMed     Text format     Abstract available


  189. SEOW CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, et al
    The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 20. doi: 10.1111/apt.14040.
    PubMed     Text format     Abstract available


  190. BONOVAS S, Fiorino G, Lytras T, Nikolopoulos G, et al
    Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Mar 6. doi: 10.1111/apt.14023.
    PubMed     Text format     Abstract available


  191. ARTOM M, Czuber-Dochan W, Norton C
    Letter: causes of fatigue in inflammatory bowel disease remain uncertain - authors' reply.
    Aliment Pharmacol Ther. 2017;45:763-764.
    PubMed     Text format    


  192. GRACIE DJ, Ford AC
    Letter: causes of fatigue in inflammatory bowel disease remain uncertain.
    Aliment Pharmacol Ther. 2017;45:762-763.
    PubMed     Text format    


  193. HEERASING N, Thompson B, Hendy P, Heap GA, et al
    Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for adults with Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:660-669.
    PubMed     Text format     Abstract available


  194. WINTER RW, Collins E, Cao B, Carrellas M, et al
    Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-alpha medications among patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:653-659.
    PubMed     Text format     Abstract available


  195. SEGAL JP, Ding NS, Worley G, Mclaughlin S, et al
    Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm.
    Aliment Pharmacol Ther. 2017;45:581-592.
    PubMed     Text format     Abstract available


  196. RADFORD-SMITH GL, Hartnell F, Doecke JD
    Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort - authors' reply.
    Aliment Pharmacol Ther. 2017;45:856-857.
    PubMed     Text format    


  197. YAMAMOTO T, Shimoyama T
    Letter: small bowel recurrence and fate of the rectum after total colectomy and ileostomy for Crohn's colitis.
    Aliment Pharmacol Ther. 2017;45:863.
    PubMed     Text format    


  198. FRASER AG
    Editorial: can we get more clinical benefit from thiopurine metabolite testing?
    Aliment Pharmacol Ther. 2017;45:857-858.
    PubMed     Text format    


  199. BARREIRO-DE ACOSTA M, Gisbert JP
    Editorial: relative efficacy of infliximab and adalimumab in Crohn's disease in an Australian and New Zealand cohort.
    Aliment Pharmacol Ther. 2017;45:855-856.
    PubMed     Text format    


  200. WONG DR, Hooymans PM
    Editorial: can we get more clinical benefit from thiopurine metabolite testing? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:858-859.
    PubMed     Text format    


  201. BEN-HORIN S, Ungar B, Roblin X
    Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab? Authors' reply.
    Aliment Pharmacol Ther. 2017;45:760-762.
    PubMed     Text format    


    February 2017
  202. SMOLINSKA A, Bodelier AG, Dallinga JW, Masclee AA, et al
    The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Feb 26. doi: 10.1111/apt.14004.
    PubMed     Text format     Abstract available


  203. STRIK AS, van den Brink GR, Ponsioen C, Mathot R, et al
    Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13994.
    PubMed     Text format     Abstract available


  204. PORTER CK, Welsh M, Riddle MS, Nieh C, et al
    Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment-related risk factors, and antecedent episodes of infectious gastroenteritis.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13991.
    PubMed     Text format     Abstract available


  205. LOPHAVEN SN, Lynge E, Burisch J
    The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study.
    Aliment Pharmacol Ther. 2017 Feb 23. doi: 10.1111/apt.13971.
    PubMed     Text format     Abstract available


  206. LAW CC, Tariq R, Khanna S, Murthy S, et al
    Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short and long-term risks of colectomy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 16. doi: 10.1111/apt.13972.
    PubMed     Text format     Abstract available


  207. MAHADEVAN U, Vermeire S, Lasch K, Abhyankar B, et al
    Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 Feb 7. doi: 10.1111/apt.13960.
    PubMed     Text format     Abstract available


  208. DOECKE JD, Hartnell F, Bampton P, Bell S, et al
    Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
    Aliment Pharmacol Ther. 2017;45:542-552.
    PubMed     Text format     Abstract available


  209. FUMERY M, Dulai PS, Meirick P, Farrell AM, et al
    Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy.
    Aliment Pharmacol Ther. 2017;45:381-390.
    PubMed     Text format     Abstract available


    January 2017
  210. DIEDEREN K, Hoekman DR, Leek A, Wolters VM, et al
    Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
    Aliment Pharmacol Ther. 2017 Jan 31. doi: 10.1111/apt.13950.
    PubMed     Text format     Abstract available


  211. VUITTON L, Peyrin-Biroulet L, Colombel JF, Pariente B, et al
    Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.
    Aliment Pharmacol Ther. 2017 Jan 23. doi: 10.1111/apt.13948.
    PubMed     Text format     Abstract available


  212. HINDRYCKX P, Novak G, Vande Casteele N, Laukens D, et al
    Review article: dose optimisation of infliximab for acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2017 Jan 11. doi: 10.1111/apt.13913.
    PubMed     Text format     Abstract available


  213. HARTERY K, O'Reilly S, Houlihan D, Doherty G, et al
    Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2017;45:376-378.
    PubMed     Text format    


  214. HONG SN, Kim HJ, Kim KH, Han SJ, et al
    Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
    Aliment Pharmacol Ther. 2017;45:253-263.
    PubMed     Text format     Abstract available


  215. GREGOIRE C, Lechanteur C, Briquet A, Baudoux E, et al
    Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2017;45:205-221.
    PubMed     Text format     Abstract available


  216. UNGAR B, Kopylov U, Engel T, Yavzori M, et al
    Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.
    Aliment Pharmacol Ther. 2017;45:276-282.
    PubMed     Text format     Abstract available


  217. PRATAP MOULI V, Munot K, Ananthakrishnan A, Kedia S, et al
    Endoscopic and clinical responses to anti-tubercular therapy can differentiate intestinal tuberculosis from Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:27-36.
    PubMed     Text format     Abstract available


  218. CHRISTENSEN B, Sparrow MP
    Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.
    Aliment Pharmacol Ther. 2017;45:178-179.
    PubMed     Text format    


    December 2016
  219. ANGELISON L, Almer S, Eriksson A, Karling P, et al
    Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients.
    Aliment Pharmacol Ther. 2016 Dec 27. doi: 10.1111/apt.13893.
    PubMed     Text format     Abstract available


  220. CARRAT F, Seksik P, Colombel JF, Peyrin-Biroulet L, et al
    The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Dec 19. doi: 10.1111/apt.13897.
    PubMed     Text format     Abstract available


  221. WONG DR, Coenen MJ, Derijks LJ, Vermeulen SH, et al
    Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Dec 12. doi: 10.1111/apt.13879.
    PubMed     Text format     Abstract available


    November 2016
  222. KONIG J, Siebenhaar A, Hogenauer C, Arkkila P, et al
    Consensus report: faecal microbiota transfer - clinical applications and procedures.
    Aliment Pharmacol Ther. 2016 Nov 27. doi: 10.1111/apt.13868.
    PubMed     Text format     Abstract available


  223. ARTOM M, Czuber-Dochan W, Sturt J, Murrells T, et al
    The contribution of clinical and psychosocial factors to fatigue in 182 patients with inflammatory bowel disease: a cross-sectional study.
    Aliment Pharmacol Ther. 2016 Nov 20. doi: 10.1111/apt.13870.
    PubMed     Text format     Abstract available


  224. FEAGAN BG, Patel H, Colombel JF, Rubin DT, et al
    Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial.
    Aliment Pharmacol Ther. 2016 Nov 17. doi: 10.1111/apt.13852.
    PubMed     Text format     Abstract available


  225. AGGIO RB, White P, Jayasena H, de Lacy Costello B, et al
    Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13822.
    PubMed     Text format     Abstract available


  226. MAO EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, et al
    Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Nov 10. doi: 10.1111/apt.13847.
    PubMed     Text format     Abstract available


  227. COLOMBEL JF, Jharap B, Sandborn WJ, Feagan B, et al
    Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
    Aliment Pharmacol Ther. 2016 Nov 7. doi: 10.1111/apt.13838.
    PubMed     Text format     Abstract available


    October 2016
  228. KIRCHGESNER J, Lemaitre M, Rudnichi A, Racine A, et al
    Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
    Aliment Pharmacol Ther. 2016 Oct 26. doi: 10.1111/apt.13835.
    PubMed     Text format     Abstract available


  229. SELINGER CP, Carbery I, Warren V, Rehman AF, et al
    The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Oct 25. doi: 10.1111/apt.13831.
    PubMed     Text format     Abstract available


  230. STALLMACH A, Langbein C, Atreya R, Bruns T, et al
    Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Aliment Pharmacol Ther. 2016 Oct 7. doi: 10.1111/apt.13813.
    PubMed     Text format     Abstract available


  231. ZHULINA Y, Cao Y, Amcoff K, Carlson M, et al
    Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2016;44:770-1.
    PubMed     Text format    


  232. YAMAMOTO T, Shimoyama T, Kuriyama M
    Letter: faecal calprotectin for the prediction of relapse in inactive inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;44:769-70.
    PubMed     Text format    


  233. CUI DJ, Chen H, Hu M
    Letter: anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 for ulcerative colitis.
    Aliment Pharmacol Ther. 2016;44:767.
    PubMed     Text format    


    September 2016
  234. D'HAENS G
    Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Sep 21. doi: 10.1111/apt.13803.
    PubMed     Text format     Abstract available


    August 2016
  235. PEYRIN-BIROULET L, Germain A, Patel AS, Lindsay JO, et al
    Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Aug 17. doi: 10.1111/apt.13763.
    PubMed     Text format     Abstract available


  236. RENNA S, Orlando E, Macaluso FS, Maida M, et al
    Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis.
    Aliment Pharmacol Ther. 2016;44:310-1.
    PubMed     Text format    


  237. DIEDEREN K, Hoekman DR, Benninga MA
    Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2016;44:309-10.
    PubMed     Text format    


  238. DAI C, Jiang M, Sun MJ
    Letter: irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;44:308-9.
    PubMed     Text format    


  239. TRIVEDI PJ, Schmidt C, Bruns T
    Letter: the therapeutic potential of targeting CCL25/CCR9 in colonic inflammatory bowel disease - reading between the lines.
    Aliment Pharmacol Ther. 2016;44:307-8.
    PubMed     Text format    


  240. BROOKS AJ, Rowse G, Ryder A, Peach EJ, et al
    Letter: risk factors and impacts of psychological morbidity in young people with inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2016;44:426.
    PubMed     Text format    


  241. QIN HG, Li LQ, Mo HY, Tan JT, et al
    Letter: risk factors and impacts of psychological morbidity in young people with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;44:425-6.
    PubMed     Text format    


    July 2016
  242. ZHULINA Y, Cao Y, Amcoff K, Carlson M, et al
    The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Jul 12. doi: 10.1111/apt.13731.
    PubMed     Text format     Abstract available


  243. CHHAYA V, Saxena S, Cecil E, Subramanian V, et al
    Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study.
    Aliment Pharmacol Ther. 2016 Jul 4. doi: 10.1111/apt.13700.
    PubMed     Text format     Abstract available


  244. BARREIRO-DE ACOSTA M, Gisbert JP
    Letter: anti-TNF in steroid-dependent ulcerative colitis - are the available data enough?
    Aliment Pharmacol Ther. 2016;44:102.
    PubMed     Text format    


    June 2016
  245. YAMAMOTO T, Shimoyama T, Umegae S, Matsumoto K, et al
    Letter: which patient profile for tacrolimus in ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2016;43:1243.
    PubMed     Text format    


  246. LAHARIE D, Poullenot F
    Letter: which patient profile for tacrolimus in ulcerative colitis?
    Aliment Pharmacol Ther. 2016;43:1242-3.
    PubMed     Text format    


  247. AHMED I, Greenwood R, Costello B, Ratcliffe N, et al
    Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease and Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Authors' reply.
    Aliment Pharmacol Ther. 2016;43:1241-2.
    PubMed     Text format    


  248. FURNARI M, Bodini G, Giannini EG, Savarino V, et al
    Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;43:1240-1.
    PubMed     Text format    


  249. SRINIVAS NR
    Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016;43:1239-40.
    PubMed     Text format    


    May 2016
  250. SCHMIDT C, Ahmad T, Tulassay Z, Baumgart DC, et al
    Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study.
    Aliment Pharmacol Ther. 2016 May 29. doi: 10.1111/apt.13665.
    PubMed     Text format     Abstract available


  251. CHEN JH, Andrews JM, Kariyawasam V, Moran N, et al
    Review article: acute severe ulcerative colitis - evidence-based consensus statements.
    Aliment Pharmacol Ther. 2016 May 26. doi: 10.1111/apt.13670.
    PubMed     Text format     Abstract available


  252. SANDBORN WJ, Bhandari BR, Fogel R, Onken J, et al
    Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis.
    Aliment Pharmacol Ther. 2016 May 24. doi: 10.1111/apt.13653.
    PubMed     Text format     Abstract available


  253. TO N, Ford AC, Gracie DJ
    Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis.
    Aliment Pharmacol Ther. 2016 May 18. doi: 10.1111/apt.13663.
    PubMed     Text format     Abstract available


  254. BROOKS AJ, Rowse G, Ryder A, Peach EJ, et al
    Systematic review: psychological morbidity in young people with inflammatory bowel disease - risk factors and impacts.
    Aliment Pharmacol Ther. 2016 May 4. doi: 10.1111/apt.13645.
    PubMed     Text format     Abstract available


  255. YAMAMOTO T, Shimoyama T, Umegae S, Matsumoto K, et al
    Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis - authors' reply.
    Aliment Pharmacol Ther. 2016;43:1017-8.
    PubMed     Text format    


  256. TAYLOR KM, Sparrow MP
    Editorial: tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis.
    Aliment Pharmacol Ther. 2016;43:1016-7.
    PubMed     Text format    


  257. GISBERT JP, Chaparro M
    Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
    Aliment Pharmacol Ther. 2016;43:1020.
    PubMed     Text format    


  258. MACALUSO FS, Criscuoli V, Orlando E, Rizzuto G, et al
    Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure.
    Aliment Pharmacol Ther. 2016;43:1019-20.
    PubMed     Text format    


  259. BUISSON A, Vazeille E, Minet-Quinard R, Goutte M, et al
    Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2016;43:1069-79.
    PubMed     Text format     Abstract available


    April 2016
  260. DIEDEREN K, Hoekman DR, Hummel TZ, de Meij TG, et al
    The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Aliment Pharmacol Ther. 2016 Apr 25. doi: 10.1111/apt.13636.
    PubMed     Text format     Abstract available


  261. UNGAR B, Mazor Y, Weisshof R, Yanai H, et al
    Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Apr 19. doi: 10.1111/apt.13631.
    PubMed     Text format     Abstract available


  262. LYNCH RW, Churchhouse AM, Protheroe A, Arnott ID, et al
    Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data.
    Aliment Pharmacol Ther. 2016 Apr 7. doi: 10.1111/apt.13614.
    PubMed     Text format     Abstract available


  263. BAUMGART DC, Bokemeyer B, Drabik A, Stallmach A, et al
    Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study.
    Aliment Pharmacol Ther. 2016 Apr 1. doi: 10.1111/apt.13594.
    PubMed     Text format     Abstract available


  264. KIRCHGESNER J, Sokol H
    Editorial: mongersen in Crohn's disease--a new contribution to the beginning of a long-awaited therapeutic revolution?
    Aliment Pharmacol Ther. 2016;43:838-9.
    PubMed     Text format    


  265. TORRES J, Bao X, Goel A, Colombel JF, et al
    The features of mucosa-associated microbiota in primary sclerosing cholangitis.
    Aliment Pharmacol Ther. 2016;43:790-801.
    PubMed     Text format     Abstract available


    March 2016
  266. SINGH S, Heien HC, Sangaralingham LR, Schilz SR, et al
    Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Mar 15. doi: 10.1111/apt.13580.
    PubMed     Text format     Abstract available


  267. TURSI A, Della Valle N, Penna A, Pranzo G, et al
    Letter: effectiveness of golimumab to induce remission in outpatient ulcerative colitis in Italy.
    Aliment Pharmacol Ther. 2016;43:657-8.
    PubMed     Text format    


  268. ELLUL P, Schembri J, Torpiano P, Borg J, et al
    Letter: abnormal bone densitometry in patients with coeliac disease -beyond malabsorption and sunlight exposure.
    Aliment Pharmacol Ther. 2016;43:658-9.
    PubMed     Text format    


  269. TAYLOR SA
    Editorial: can MRI enterography be an efficient tool for patient selection in clinical trials?
    Aliment Pharmacol Ther. 2016;43:643-4.
    PubMed     Text format    


  270. SIEGEL CA, Dubinsky MC
    Editorial: how to interpret risks and prediction of complications in Crohn's disease--can our patients interpret them? Authors' reply.
    Aliment Pharmacol Ther. 2016;43:653.
    PubMed     Text format    


  271. ROGLER G
    Editorial: how to interpret risks and prediction of complications in Crohn's disease--can our patients interpret them?
    Aliment Pharmacol Ther. 2016;43:651-2.
    PubMed     Text format    


  272. TO N, Gracie DJ, Ford AC
    Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:549-61.
    PubMed     Text format     Abstract available


  273. VEDAK P, Kroshinsky D, St John J, Xavier RJ, et al
    Genetic basis of TNF-alpha antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis.
    Aliment Pharmacol Ther. 2016;43:697-704.
    PubMed     Text format     Abstract available


  274. MONTELEONE G, Di Sabatino A, Ardizzone S, Pallone F, et al
    Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:717-24.
    PubMed     Text format     Abstract available


    February 2016
  275. KENNEDY NA, Warner B, Johnston EL, Flanders L, et al
    Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.
    Aliment Pharmacol Ther. 2016 Feb 19. doi: 10.1111/apt.13547.
    PubMed     Text format     Abstract available


  276. MOON W, Loftus EV Jr
    Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Feb 14. doi: 10.1111/apt.13559.
    PubMed     Text format     Abstract available


  277. MARCHAL BRESSENOT A, Peyrin-Biroulet L
    Letter: histological assessment of disease activity in ulcerative colitis - the problem of score evaluation and validation; authors' reply.
    Aliment Pharmacol Ther. 2016;43:439.
    PubMed     Text format    


  278. VILLANACCI V, Salemme M, Bassotti G, Antonelli E, et al
    Letter: histological assessment of disease activity in ulcerative colitis - the problem of score evaluation and validation.
    Aliment Pharmacol Ther. 2016;43:438-9.
    PubMed     Text format    


  279. DE BIE C, Ferrante M
    Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. Authors' reply.
    Aliment Pharmacol Ther. 2016;43:441.
    PubMed     Text format    


  280. TO N, Gracie DJ, Ford AC
    Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:440.
    PubMed     Text format    


  281. SHAH SC, Colombel JF, Sands BE, Narula N, et al
    Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease.
    Aliment Pharmacol Ther. 2016;43:317-33.
    PubMed     Text format     Abstract available


    January 2016
  282. AHMED I, Greenwood R, Costello B, Ratcliffe N, et al
    Investigation of faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2016 Jan 25. doi: 10.1111/apt.13522.
    PubMed     Text format     Abstract available


  283. YAMAMOTO T, Shimoyama T, Umegae S, Matsumoto K, et al
    Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
    Aliment Pharmacol Ther. 2016 Jan 13. doi: 10.1111/apt.13531.
    PubMed     Text format     Abstract available


  284. FEVERY J, Van Steenbergen W, Van Pelt J, Laleman W, et al
    Patients with large-duct primary sclerosing cholangitis and Crohn's disease have a better outcome than those with ulcerative colitis, or without IBD.
    Aliment Pharmacol Ther. 2016 Jan 8. doi: 10.1111/apt.13516.
    PubMed     Text format     Abstract available


  285. SEAH D, De Cruz P
    Review article: the practical management of acute severe ulcerative colitis.
    Aliment Pharmacol Ther. 2016 Jan 4. doi: 10.1111/apt.13491.
    PubMed     Text format     Abstract available


  286. AMIOT A, Stefanescu C, Bouhnik Y
    Editorial: what can be done when infliximab stops working in ulcerative colitis? Authors' reply.
    Aliment Pharmacol Ther. 2016;43:165.
    PubMed     Text format    


  287. BOYAPATI RK, Ho GT, Satsangi J
    Editorial: what can be done when infliximab stops working in ulcerative colitis?
    Aliment Pharmacol Ther. 2016;43:164.
    PubMed     Text format    


  288. YAMAMOTO T, Shimoyama T, Matsumoto K
    Letter: wide variation in faecal calprotectin values according to the assay - authors' reply.
    Aliment Pharmacol Ther. 2016;43:178.
    PubMed     Text format    


  289. SUN S, Cavey T, Peltier L, Bendavid C, et al
    Letter: wide variation in faecal calprotectin values according to the assay.
    Aliment Pharmacol Ther. 2016;43:177-8.
    PubMed     Text format    


  290. DE CRUZ P, Kamm MA
    Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab- authors' reply.
    Aliment Pharmacol Ther. 2016;43:170-1.
    PubMed     Text format    


  291. AGUAS M, Nos P, Gisbert JP
    Letter: management of post-operative Crohn's disease - thiopurines vs adalimumab.
    Aliment Pharmacol Ther. 2016;43:168-9.
    PubMed     Text format    


  292. SARTOR RB
    Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2016;43 Suppl 1:27-36.
    PubMed     Text format     Abstract available


  293. DUPONT HL
    Introduction: understanding mechanisms of the actions of rifaximin in selected gastrointestinal diseases.
    Aliment Pharmacol Ther. 2016;43 Suppl 1:1-2.
    PubMed     Text format     Abstract available


  294. COIMBRA AJ, Rimola J, O'Byrne S, Lu TT, et al
    Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation.
    Aliment Pharmacol Ther. 2016;43:61-72.
    PubMed     Text format     Abstract available


  295. DING NS, Hart A, De Cruz P
    Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.
    Aliment Pharmacol Ther. 2016;43:30-51.
    PubMed     Text format     Abstract available


  296. SIEGEL CA, Horton H, Siegel LS, Thompson KD, et al
    A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables.
    Aliment Pharmacol Ther. 2016;43:262-71.
    PubMed     Text format     Abstract available


    November 2015
  297. FUMERY M, Duricova D, Gower-Rousseau C, Annese V, et al
    Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies.
    Aliment Pharmacol Ther. 2015 Nov 18. doi: 10.1111/apt.13478.
    PubMed     Text format     Abstract available


  298. BOURRIER A, Carrat F, Colombel JF, Bouvier AM, et al
    Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
    Aliment Pharmacol Ther. 2015 Nov 9. doi: 10.1111/apt.13466.
    PubMed     Text format     Abstract available


  299. GUPTA V, Rodrigues R, Nguyen D, Sauk J, et al
    Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis.
    Aliment Pharmacol Ther. 2015 Nov 5. doi: 10.1111/apt.13454.
    PubMed     Text format     Abstract available


  300. BUURMAN DJ, Maurer JM, Keizer RJ, Kosterink JG, et al
    Letter: infliximab therapy for patients with inflammatory bowel disease - some unanswered questions. Authors' reply.
    Aliment Pharmacol Ther. 2015;42:1134.
    PubMed     Text format    


  301. SRINIVAS NR
    Letter: infliximab therapy for patients with inflammatory bowel disease - some unanswered questions.
    Aliment Pharmacol Ther. 2015;42:1133.
    PubMed     Text format    


  302. HAWTHRONE AB
    Editorial: preventing disease progression in Crohn's--can we shut the stable door before the horse bolts?
    Aliment Pharmacol Ther. 2015;42:1131-2.
    PubMed     Text format    


    October 2015
  303. DE BIE C, Ballet V, Hendriks N, Coenen S, et al
    Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015 Oct 4. doi: 10.1111/apt.13423.
    PubMed     Text format     Abstract available


  304. CHAPARRO M, Gisbert JP
    Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2015;42:940-1.
    PubMed     Text format    


  305. PAUL S, Roblin X, Peyrin-Biroulet L
    Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015;42:939-40.
    PubMed     Text format    


  306. GUPTA A, De Felice KM, Loftus EV Jr, Khanna S, et al
    Letter: anti-CTLA-4-associated colitis and inflammatory bowel disease pathogenesis - authors' reply.
    Aliment Pharmacol Ther. 2015;42:1032-3.
    PubMed     Text format    


  307. MATUCHANSKY C
    Letter: anti-CTLA-4-associated colitis and inflammatory bowel disease pathogenesis.
    Aliment Pharmacol Ther. 2015;42:1031-2.
    PubMed     Text format    


    September 2015
  308. JAIRATH V, Khanna R, Zou GY, Stitt L, et al
    Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials.
    Aliment Pharmacol Ther. 2015 Sep 21. doi: 10.1111/apt.13408.
    PubMed     Text format     Abstract available


  309. DUMITRESCU G, Amiot A, Seksik P, Baudry C, et al
    The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab.
    Aliment Pharmacol Ther. 2015 Sep 10. doi: 10.1111/apt.13393.
    PubMed     Text format     Abstract available


  310. JHARAP B, Sandborn WJ, Reinisch W, D'Haens G, et al
    Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis.
    Aliment Pharmacol Ther. 2015 Sep 3. doi: 10.1111/apt.13387.
    PubMed     Text format     Abstract available


    August 2015
  311. MARCHAL BRESSENOT A, Riddell RH, Boulagnon-Rombi C, Reinisch W, et al
    Review article: the histological assessment of disease activity in ulcerative colitis.
    Aliment Pharmacol Ther. 2015 Aug 24. doi: 10.1111/apt.13375.
    PubMed     Text format     Abstract available


  312. CHHAYA V, Pollok RC, Cecil E, Subramanian V, et al
    Impact of early thiopurines on surgery in 2770 children and young people diagnosed with inflammatory bowel disease: a national population-based study.
    Aliment Pharmacol Ther. 2015 Aug 13. doi: 10.1111/apt.13361.
    PubMed     Text format     Abstract available


  313. BAN L, Tata LJ, Humes DJ, Fiaschi L, et al
    Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study.
    Aliment Pharmacol Ther. 2015 Aug 6. doi: 10.1111/apt.13354.
    PubMed     Text format     Abstract available


  314. BUISSON A, Hordonneau C, Goutte M, Boyer L, et al
    Diffusion-weighted magnetic resonance imaging is effective to detect ileocolonic ulcerations in Crohn's disease.
    Aliment Pharmacol Ther. 2015;42:452-60.
    PubMed     Text format     Abstract available


  315. MOON W, Pestana L, Becker B, Loftus EV Jr, et al
    Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice.
    Aliment Pharmacol Ther. 2015;42:428-40.
    PubMed     Text format     Abstract available


  316. PLUMB AA, Menys A, Russo E, Prezzi D, et al
    Magnetic resonance imaging-quantified small bowel motility is a sensitive marker of response to medical therapy in Crohn's disease.
    Aliment Pharmacol Ther. 2015;42:343-55.
    PubMed     Text format     Abstract available


  317. BEN-HORIN S, Chowers Y, Ungar B, Kopylov U, et al
    Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal.
    Aliment Pharmacol Ther. 2015;42:356-64.
    PubMed     Text format     Abstract available


  318. SANDBORN WJ, Melmed GY, McGovern DP, Loftus EV Jr, et al
    Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.
    Aliment Pharmacol Ther. 2015;42:330-42.
    PubMed     Text format     Abstract available


    July 2015
  319. PUGLIESE D, Guidi L, Ferraro PM, Marzo M, et al
    Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
    Aliment Pharmacol Ther. 2015 Jul 31. doi: 10.1111/apt.13352.
    PubMed     Text format     Abstract available


  320. HOURIGAN SK, Chen LA, Grigoryan Z, Laroche G, et al
    Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015 Jul 21. doi: 10.1111/apt.13326.
    PubMed     Text format     Abstract available


  321. SAFRONEEVA E, Vavricka S, Fournier N, Seibold F, et al
    Systematic analysis of factors associated with progression and regression of ulcerative colitis in 918 patients.
    Aliment Pharmacol Ther. 2015 Jul 6. doi: 10.1111/apt.13307.
    PubMed     Text format     Abstract available


  322. YAMAMOTO T, Shimoyama T, Matsumoto K
    Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
    Aliment Pharmacol Ther. 2015 Jul 3. doi: 10.1111/apt.13308.
    PubMed     Text format     Abstract available


  323. CICCOCIOPPO R
    Letter: cytomegalovirus infection in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015;42:127-9.
    PubMed     Text format    


  324. ROSEN MJ, Minar P, Vinks AA
    Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease - authors' reply.
    Aliment Pharmacol Ther. 2015;42:241.
    PubMed     Text format    


  325. ROBLIN X, Paul S
    Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease.
    Aliment Pharmacol Ther. 2015;42:240.
    PubMed     Text format    


  326. ANANTHAKRISHNAN AN
    Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases - author's reply.
    Aliment Pharmacol Ther. 2015;42:120.
    PubMed     Text format    


  327. TAYLOR KM, Sparrow MP
    Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2015;42:119-20.
    PubMed     Text format    


  328. KATSANOS KH, Torres J, Roda G, Brygo A, et al
    Review article: non-malignant oral manifestations in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2015;42:40-60.
    PubMed     Text format     Abstract available


    June 2015
  329. RUTGEERTS P, Feagan BG, Marano CW, Padgett L, et al
    Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.
    Aliment Pharmacol Ther. 2015 Jun 29. doi: 10.1111/apt.13291.
    PubMed     Text format     Abstract available


  330. BUURMAN DJ, Maurer JM, Keizer RJ, Kosterink JG, et al
    Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice.
    Aliment Pharmacol Ther. 2015 Jun 26. doi: 10.1111/apt.13299.
    PubMed     Text format     Abstract available


  331. LOBATON T, Ferrante M, Rutgeerts P, Ballet V, et al
    Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015 Jun 24. doi: 10.1111/apt.13294.
    PubMed     Text format     Abstract available


  332. GISBERT JP, Marin AC, Chaparro M
    Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy.
    Aliment Pharmacol Ther. 2015 Jun 15. doi: 10.1111/apt.13276.
    PubMed     Text format     Abstract available


  333. THANGARAJAH D, Hyde MJ, Konteti VK, Santhakumaran S, et al
    Systematic review: body composition in children with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015 Jun 4. doi: 10.1111/apt.13218.
    PubMed     Text format     Abstract available


  334. BRYANT RV, Andrews JM
    Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease - authors' reply.
    Aliment Pharmacol Ther. 2015;41:1304-5.
    PubMed     Text format    


  335. DEFILIPPIS EM, Webb C, Warren RU, Tabani S, et al
    Letter: low muscle mass and disordered eating as causes of osteopenia in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2015;41:1303-4.
    PubMed     Text format    


  336. ASSIS DN, Levy C
    Editorial: environmental risk factors for PSC with and without IBD--the story unfolds.
    Aliment Pharmacol Ther. 2015;41:1214-6.
    PubMed     Text format    


  337. COLOMBEL JF, Cornillie F, Bevelander G
    Editorial: post hoc analysis of SONIC trial--authors' reply.
    Aliment Pharmacol Ther. 2015;41:1211.
    PubMed     Text format    


  338. FRASER AG
    Editorial: post hoc analysis of SONIC trial.
    Aliment Pharmacol Ther. 2015;41:1210.
    PubMed     Text format    


  339. GISBERT JP, Chaparro M
    Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
    Aliment Pharmacol Ther. 2015;41:1302-3.
    PubMed     Text format    


  340. LICINIO R, Losurdo G, Ierardi E, Di Leo A, et al
    Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic.
    Aliment Pharmacol Ther. 2015;41:1302.
    PubMed     Text format    


  341. ANANTHAKRISHNAN AN, Cagan A, Cai T, Gainer VS, et al
    Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2015;41:1141-8.
    PubMed     Text format     Abstract available


  342. MOJA L, Danese S, Fiorino G, Del Giovane C, et al
    Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease.
    Aliment Pharmacol Ther. 2015;41:1055-65.
    PubMed     Text format     Abstract available


    May 2015
  343. ROSARIO M, Dirks NL, Gastonguay MR, Fasanmade AA, et al
    Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
    Aliment Pharmacol Ther. 2015 May 20. doi: 10.1111/apt.13243.
    PubMed     Text format     Abstract available


  344. NORTON C, Czuber-Dochan W, Bassett P, Berliner S, et al
    Assessing fatigue in inflammatory bowel disease: comparison of three fatigue scales.
    Aliment Pharmacol Ther. 2015 May 19. doi: 10.1111/apt.13255.
    PubMed     Text format     Abstract available


  345. CASEN C, Vebo HC, Sekelja M, Hegge FT, et al
    Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD.
    Aliment Pharmacol Ther. 2015 May 14. doi: 10.1111/apt.13236.
    PubMed     Text format     Abstract available


  346. LUNNEY PC, Kariyawasam VC, Wang RR, Middleton KL, et al
    Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis.
    Aliment Pharmacol Ther. 2015 May 12. doi: 10.1111/apt.13239.
    PubMed     Text format     Abstract available


  347. VAN LANGENBERG DR, Papandony MC, Gibson PR
    Sleep and physical activity measured by accelerometry in Crohn's disease.
    Aliment Pharmacol Ther. 2015;41:991-1004.
    PubMed     Text format     Abstract available


    April 2015
  348. CSONTOS AA, Molnar A, Miheller P
    Letter: body surface area and body muscle parameters may influence adalimumab trough levels.
    Aliment Pharmacol Ther. 2015;41:700.
    PubMed     Text format    


  349. KURADA S, Alkhouri N, Fiocchi C, Dweik R, et al
    Letter: volatile metabolomics of exhaled breath or faecal gas? - authors' reply.
    Aliment Pharmacol Ther. 2015;41:704.
    PubMed     Text format    


  350. DE GROOT EF, de Meij TG, van der Schee MP, de Boer NK, et al
    Letter: volatile metabolomics of exhaled breath or faecal gas?
    Aliment Pharmacol Ther. 2015;41:703.
    PubMed     Text format    


  351. GERICH M, Yoon J, Vasiliauskas E
    Editorial: is thalidomide a good option for patients with refractory Crohn's disease? Authors' reply.
    Aliment Pharmacol Ther. 2015;41:786.
    PubMed     Text format    


  352. ROGLER G
    Editorial: is thalidomide a good option for patients with refractory Crohn's disease?
    Aliment Pharmacol Ther. 2015;41:785-6.
    PubMed     Text format    


  353. COLOMBEL JF, Reinisch W, Mantzaris GJ, Kornbluth A, et al
    Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease - a SONIC post hoc analysis.
    Aliment Pharmacol Ther. 2015;41:734-46.
    PubMed     Text format     Abstract available


    March 2015
  354. SUBRAMANIAM K, Fallon K, Ruut T, Lane D, et al
    Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn's disease.
    Aliment Pharmacol Ther. 2015;41:419-28.
    PubMed     Text format     Abstract available


  355. GERICH ME, Yoon JL, Targan SR, Ippoliti AF, et al
    Long-term outcomes of thalidomide in refractory Crohn's disease.
    Aliment Pharmacol Ther. 2015;41:429-37.
    PubMed     Text format     Abstract available


    February 2015
  356. KURADA S, Alkhouri N, Fiocchi C, Dweik R, et al
    Review article: breath analysis in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2015;41:329-41.
    PubMed     Text format     Abstract available


    January 2015
  357. FELICE C, Lewis A, Armuzzi A, Lindsay JO, et al
    Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.
    Aliment Pharmacol Ther. 2015;41:26-38.
    PubMed     Text format     Abstract available


  358. KHANNA R, Zou G, D'Haens G, Feagan BG, et al
    A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity.
    Aliment Pharmacol Ther. 2015;41:77-86.
    PubMed     Text format     Abstract available


  359. CHURCH PC, Turner D, Feldman BM, Walters TD, et al
    Systematic review with meta-analysis: magnetic resonance enterography signs for the detection of inflammation and intestinal damage in Crohn's disease.
    Aliment Pharmacol Ther. 2015;41:153-66.
    PubMed     Text format     Abstract available


    December 2014
  360. PLENER I, Ferguson C, Kashkooli S, Saibil F, et al
    Oral B12 replacement in Crohn's disease - is B12 by injection obsolete?
    Aliment Pharmacol Ther. 2014;40.
    PubMed     Text format    


    November 2014
  361. LIE MR, Peppelenbosch MP, West RL, Zelinkova Z, et al
    Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment.
    Aliment Pharmacol Ther. 2014;40:1202-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: